Phase 1 Study of EGFR-antisense DNA, Cetuximab, and Radiotherapy in Head and Neck Cancer With Preclinical Correlatives

Cancer - United States
doi 10.1002/cncr.31651
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Lymphotoxin-Β Interacts With Methylated EGFR to Mediate Acquired Resistance to Cetuximab in Head and Neck Cancer

Clinical Cancer Research
Cancer ResearchOncology
2017English

Place in Concomitant Use With Anti-Egfr Radiotherapy in Locally Advanced Head and Neck Cancer Treatment

Meandros Medical and Dental Journal
2018English

Platinum-Based Chemotherapy Plus Cetuximab in Head and Neck Cancer

New England Journal of Medicine
Medicine
2008English

Cetuximab in Locally Advanced Head-And-Neck Cancer: Defining the Population

Current Oncology
Oncology
2010English

Study of Hypofractionated Radiotherapy Regime for Locally Advanced Head and Neck Cancer

Journal of Medical Science And clinical Research
2019English

Evaluation of Weekly Paclitaxel, Carboplatin, and Cetuximab in Head and Neck Cancer Patients With Incurable Disease

International Journal of Radiation Oncology Biology Physics
OncologyRadiologyCancer ResearchRadiationNuclear MedicineImaging
2016English

Cetuximab Promotes Epithelial to Mesenchymal Transition and Cancer Associated Fibroblasts in Patients With Head and Neck Cancer

Oncotarget
Oncology
2015English

Cardiovascular Risk and Prevention in Patients With Head and Neck Cancer Treated With Radiotherapy

Head and Neck
Otorhinolaryngology
2016English

Phase I Trial of Concomitant Hyperfractionated Radiotherapy With Docetaxel and Cisplatin for Locally Advanced Head and Neck Cancer

Cancer Journal
Cancer ResearchOncology
2006English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy